Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neuro-Oncology Medical Advisory Board WALNUT CREEK, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately-held oncology company focused on tough-to-treat cancers, is honored to...

Dr. Gerard Blobe, M.D., Ph.D., Joins Vivacitas Oncology's Solid Tumor Medical Advisory Board WALNUT CREEK, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held oncology company focused on tough-to-treat cancers, proudly announces that Dr. Gerard Blobe, M.D.,...

Dr. Volker W. Stieber, MD, Joins Vivacitas' Neuro-Oncology Advisory Board WALNUT CREEK, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough-to-treat cancers, is proud to present Dr. Volker W....

Vivacitas Oncology Welcomes Dr. Jai Grewal, MD, and Expands Its Neuro-Oncology Advisory Board WALNUT CREEK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately held oncology company focused on tough-to-treat cancers, is pleased to...

Vivacitas Oncology Presents Its New Neuro-Oncology Advisor, Dr. Andrew Lassman MD, MS, FAAN WALNUT CREEK, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately-held oncology company focused on tough-to-treat cancers, is pleased to...